The FDA approved Neuraceq for PET imaging of the brain to identify beta-amyloid neuritic plaque in patients with cognitive decline or Alzheimer’s disease.
The U.S. Food and Drug Administration (FDA) announced today its approval for Neuraceq, which is indicated for PET imaging of the brain to estimate beta-amyloid neuritic plaque density in cognitively impaired adult patients being evaluated for Alzheimer’s disease or other cognitive decline.
There are over seven million new cases of dementia each year worldwide, with Alzheimer’s disease accounting for 60 percent to 80 percent of all dementia diagnoses. Studies have shown that Alzheimer’s gets incorrectly diagnosed in 10 percent to 30 percent of cases, leaving many patients without appropriate treatment.
The Centers for Medicare and Medicaid Services has stated it will cover a beta-amyloid PET scan for patients under Coverage with Evidence Development programs, which aim to assess the impact of beta-amyloid scans on improving patient outcomes or advancing treatment options. Beta-amyloid is the primary indicator of Alzheimer’s.
The FDA approval was based on safety data from 872 patients who participated in global clinical trials, and three studies that examined images from adults with a range of cognitive function. The studies included 205 end-of-life patients who had agreed to participate in a post-mortem brain donation program. Images were analyzed from 82 subjects with post-mortem confirmation of the presence or absence of beta-amyloid neuritic plaques. Correlation of the visual PET interpretation with histopathology in these 82 brains demonstrated that Neuraceq accurately detects moderate to frequent beta-amyloid neuritic plaques in the brain and could be useful in estimating the density of these plaques in life.
Neuraceq is manufactured by Piramal Imaging, a division of Piramal Enterprises, Ltd.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
Can CT-Based Deep Learning Bolster Prognostic Assessments of Ground-Glass Nodules?
June 19th 2025Emerging research shows that a multiple time-series deep learning model assessment of CT images provides 20 percent higher sensitivity than a delta radiomic model and 56 percent higher sensitivity than a clinical model for prognostic evaluation of ground-glass nodules.